TPO and hypothyroidism: A TSH level equal to or more than 7 μIU/L (33.4% of the patients with SCH) and positive anti-TPO antibodies (36.1% of the patients with SCH) among SCH patients is regarded as a potential indication for initiating T4 therapy, aiming to mitigate the risk of cardiovascular complications and progression to overt hypothyroidism [8].